[Thrombotic thrombocytopenic purpura mediated by an ADAMTS13-inhibitor related to a treatment with pegylated-interferon alpha-2a and ribavirine in a patient with chronic hepatitis C].
Lambot
Frédéric
F
Hôpital Molière-Longchamps, HIS, médecine interne, Bruxelles, 1190 Bruxelles, Belgique. frederic.lambot@ulb.ac.be
Hanson
Bernard
B
Sztern
Bernard
B
D051722:ADAM Proteins / Q000276:immunology; D000071120:ADAMTS13 Protein; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D001323:Autoantibodies / Q000276:immunology; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced / Q000276:immunology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D001323:Autoantibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human; C100416:peginterferon alfa-2a